 |
|
CLINICIAN’S CORNER
Management of Antiphospholipid Antibody Syndrome
A Systematic Review
Wendy Lim, MD;
Mark A. Crowther, MD;
John W. Eikelboom, MBBS
JAMA. 2006;295:1050-1057.
ABSTRACT
| |
Context Antiphospholipid antibodies are autoantibodies directed against proteins that bind to phospholipid. Antiphospholipid antibody syndrome (APS) refers to the association between antiphospholipid antibodies and thrombosis risk or pregnancy morbidity. Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss.
Objective To systematically review the evidence for treatment of thrombosis risk in patients with antiphospholipid antibodies or APS.
Evidence Acquisition Search of MEDLINE (1966 to November 2005) and Cochrane Library electronic databases (2005) and reference lists for randomized trials, meta-analyses of randomized trials, and prospective cohort studies of the treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Studies were selected on the basis of clinical relevance.
Evidence Synthesis Among patients with antiphospholipid antibodies, the absolute risk of developing new thrombosis is low (<1% per year) in otherwise healthy patients without prior thrombotic events, may be moderately increased (up to 10% per year) in women with recurrent fetal loss without prior thrombosis, and is highest (>10% in the first year) in patients with a history of venous thrombosis who have discontinued anticoagulant drugs within 6 months. Compared with placebo or untreated control, anticoagulation with moderate-intensity warfarin (adjusted to a target international normalized ratio [INR] of 2.0-3.0) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies and may be effective for preventing recurrent arterial thrombosis. No evidence exists that high-intensity warfarin (target INR, >3.0) is more effective than moderate-intensity warfarin. For patients with a single positive antiphospholipid antibody test result and prior stroke, aspirin and moderate-intensity warfarin appear equally effective for preventing recurrent stroke. Treatment issues that have not been addressed in clinical trials, or for which the evidence is conflicting, include the role of antithrombotic prophylaxis in patients with antiphospholipid antibodies without prior thrombosis, the optimal treatment of noncerebrovascular arterial thrombosis, recurrent thrombosis despite warfarin therapy, and treatment of women with antiphospholipid antibodies and recurrent fetal loss.
Conclusions In patients with APS, moderate-intensity warfarin is effective for preventing recurrent venous thrombosis and perhaps also arterial thrombosis. Aspirin appears to be as effective as moderate-intensity warfarin for preventing recurrent stroke in patients with prior stroke and a single positive test result for antiphospholipid antibody. The optimal treatment of other thrombotic aspects of APS needs to be addressed in well-designed prospective studies.
INTRODUCTION
Antiphospholipid antibodies were first described in 1906 in a study by Wassermann et al1 among patients with positive serologic test results for syphilis. Antiphospholipid antibodies are a heterogeneous group of autoantibodies directed against phospholipid-binding proteins. Antiphospholipid antibodies can be broadly categorized into those antibodies that prolong phospholipid-dependent coagulation assays, known as lupus anticoagulants (LA), or anticardiolipin antibodies (aCL), which target a molecular congener of cardiolipin (a bovine cardiac protein). The presence of these antibodies in patients with arterial or venous thrombosis or pregnancy morbidity comprises the antiphospholipid antibody syndrome (APS). This syndrome is referred to as primary APS when it occurs alone and secondary APS when it occurs in association with other conditions, such as systemic lupus erythematosus (SLE). Antiphospholipid antibodies are also found in patients with infections such as human immunodeficiency virus2 and may develop during therapy with medications such as chlorpromazine.3-4 Their clinical importance in these settings is unknown. The Sapporo criteria are a widely used consensus definition of APS.5
Treatment of antiphospholipid antibodies is problematic because of a lack of laboratory standardization, limited data on their natural history, and a lack of randomized treatment trials. Depending on the assay, antiphospholipid antibodies are reported in up to 10% of healthy individuals and in 30% to 50% of patients with SLE.6 Antiphospholipid antibodies are more common in patients with thrombosis but a causal association is unproven and the clinical relevance of transient or low titer antiphospholipid antibodies remains uncertain. Furthermore, a recent systematic review has questioned the association between isolated aCL and thrombosis.7
We systematically reviewed laboratory testing, diagnostic criteria, and treatment of thrombosis in patients with antiphospholipid antibodies. We reviewed the management of antiphospholipid antibody–associated recurrent fetal loss but did not address preconception anticoagulation. The treatment of patients who are pregnant and develop thrombotic complications is the same irrespective of the presence of antiphospholipid antibodies and is addressed in comprehensive reviews and guidelines.8-9 We did not consider the treatment of antiphospholipid antibody–associated thrombocytopenia or catastrophic APS.
EVIDENCE ACQUISITION
We searched MEDLINE (1966 to November 2005), The Cochrane Library (2005, Issue 4), and The Cochrane Pregnancy and Childbirth Group (The Cochrane Library 2005, Issue 2) databases using the following terms singly and in combination: antiphospholipid (antibody) syndrome, antiphospholipid antibody, lupus anticoagulant, anticardiolipin antibody, thrombosis, (deep) venous thrombosis, pulmonary embolism, arterial thrombosis, arterial occlusive disease, cerebrovascular disorders, stroke, myocardial infarction, anticoagulants, platelet aggregation inhibitors, warfarin, antiplatelet, aspirin, incidence, prevalence, pregnancy, and pregnancy loss. We further reviewed reference lists and articles from the authors' libraries. We based our recommendations concerning laboratory testing and diagnosis of APS on published international consensus guidelines. In evaluating thrombosis treatment, we focused on randomized controlled trials or meta-analyses of randomized controlled trials. If these trials were not available, prospective studies were examined before retrospective studies.
EVIDENCE SYNTHESIS
Laboratory Detection of Antiphospholipid Antibodies
Laboratory testing for antiphospholipid antibodies is complicated because there is uncertainty about their antigenic target. Both LA and aCL may demonstrate specificity for  2-glycoprotein I,10-11 but many other antigenic targets have been described including prothrombin12 and annexin V.13 In some cases, antibodies directed against 2-glycoprotein I rather than anionic phospholipids are believed causal in this syndrome.14 Consensus guidelines describing laboratory techniques for measuring aCL and LA have been published.15-16
Lupus Anticoagulants
Lupus anticoagulants, also referred to as nonspecific inhibitors, are antibodies that block phospholipid surfaces important for coagulation. They reduce the coagulant potential of the plasma and prolong the clotting time in coagulation tests based on the activated partial thromboplastin time.17 Failure of the prolonged clotting time to correct after a 1:1 mix with normal platelet-free plasma and correction of the clotting time after addition of excess phospholipids confirms the presence of LA.18 Consensus guidelines recommend screening for LA with 2 or more phospholipid-dependent coagulation tests, including the activated partial thromboplastin time, dilute Russell viper venom time, kaolin clotting time, dilute prothrombin time, textarin time, or taipan time.18 Anticoagulant therapy may interfere with the detection of LA.19
Anticardiolipin Antibodies
Anticardiolipin antibodies share a common in vitro binding affinity for cardiolipin and can be detected using enzyme-linked immunosorbent assays. The immunoglobulin isotype may be IgG, IgM, or IgA. It is widely believed that the IgG isotype is most strongly associated with thrombosis, although this has not been tested in large prospective studies.20 Enzyme-linked immunosorbent assay tests for aCL are poorly standardized and aCL testing has shown poor concordance between laboratories.17 Anticardiolipin antibodies are reported as a titer specific to the isotype (IgG, IgM, or IgA phospholipid antibody titer), but because the accuracy and reliability of assays are limited, consensus guidelines recommend semiquantitative reporting of results (low, medium, or high titer).21
Anti–2-Glycoprotein I Antibodies
Anti-2–glycoprotein I antibodies22-23 are currently not included in the Sapporo criteria but may be incorporated in future updates. The laboratory assay for these antibodies is not standardized, making comparison between studies difficult.11 The clinical relevance of anti–2-glycoprotein I antibodies also is uncertain, although there is some evidence that these antibodies are more specific for APS.24
Diagnostic Criteria for APS
According to the Sapporo criteria, APS is present in patients with 1 clinical and 1 laboratory criterion. Clinical criteria include objectively confirmed arterial, venous, or small-vessel thrombosis, or pregnancy morbidity consisting of recurrent fetal loss before the 10th week of gestation, 1 or more unexplained fetal death at or beyond the 10th week of gestation, or premature birth due to placental insufficiency, eclampsia, or preeclampsia. Laboratory criteria include medium or high titer IgG or IgM aCL or the presence of LA on 2 or more occasions at least 6 weeks apart.15-16
Although consensus-derived diagnostic criteria such as those formulated by the Sapporo international workshop require repeated measurement to establish a diagnosis of APS, there is no evidence that transient antiphospholipid antibodies are less important than persistent antibodies. Two of the largest studies to examine the prognostic importance of antiphospholipid antibodies tested patients on only one occasion: at the time of presentation with stroke25 and 6 months following the diagnosis of venous thromboembolism.26
Association of Antiphospholipid Antibodies and Thrombosis
Cross-sectional studies among healthy blood donors report LA in 8% of patients,27 IgG aCL in 6.5% of patients, and IgM aCL in 9.4% of patients.28 Persistently positive antiphospholipid antibodies are unusual in healthy individuals (<2% of healthy blood donors initially found to have aCL still had increased levels 9 months later).28 In a general obstetric population, the prevalence of LA was 0.3% and the prevalence of aCL was 2.2% to 9.1%, which was similar to that observed among patients who are not pregnant (5.6%).29-30 In comparison, the prevalence of antiphospholipid antibodies appears to be higher, in the range of 4% to 21%, among patients presenting with thrombosis.31-32 The increased prevalence of antiphospholipid antibodies among patients with thrombosis suggests an association between antiphospholipid antibodies and thrombosis, and the increasing risk of thrombosis among those patients with increasing antibody titers further strengthens the evidence that the association is causal. However, there remains controversy about the true nature of this relationship, which may also be confounded by the presence of unmeasured LA.33
The association between antiphospholipid antibodies and thrombosis is stronger with LA than with aCL. In a meta-analysis of 25 studies involving more than 7000 patients, the mean odds ratio (OR) for thrombosis was 1.6 for aCL and 11.0 for LA,7 which is consistent with the results of an earlier meta-analysis of 6 studies.34 However, these meta-analyses are limited by the quality of the included studies; there are no large prospective studies of unselected patients whose antiphospholipid antibody status was determined before objective documentation of thrombotic complications.
In the Framingham Heart Study cohort, increased aCL was independently associated with an increased risk of ischemic stroke or transient ischemic attack in women (hazard ratio [HR], 2.6; absolute risk, 3.2%) but not in men (HR, 1.3; absolute risk, 4.5%).35
Thrombosis is presumed to cause many of the pregnancy complications associated with APS. In women without SLE, a retrospective review of more than 13 000 patients found a prevalence of antiphospholipid antibodies of 20% among women with recurrent fetal loss compared with 5% in healthy women.36 The association between antiphospholipid antibodies and fetal loss is strongest for loss occurring after 10 weeks.37 The association between antiphospholipid antibodies and the risk of premature birth due to eclampsia or preeclampsia and intrauterine growth restriction remains controversial; studies contributing data to this area tend to be small, retrospective, and have conflicting results.38-39 Furthermore, the toxicity of treatments evaluated in these studies may contribute to pregnancy loss or complication and may confound the association between antiphospholipid antibodies and adverse pregnancy outcomes.40
Determining Thrombosis Risk in APS
The optimal treatment of thrombosis risk in patients with APS requires assessment of thrombosis risk associated with antiphospholipid antibodies so that the potential benefits of antithrombotic therapies for preventing thrombosis can be balanced against the risk of bleeding.
Patients Without Prior Thrombosis. In patients with SLE, the incidence of thrombosis was 2 per 100 person-years in a prospective cohort of 551 patients of whom 49% had either LA or aCL.41 The OR of thrombosis was 3.20 (95% confidence interval [CI], 1.43-7.14) for LA and 6.80 (95% CI, 1.53-30.20) for high-titer aCL. However, patients with SLE have a high prevalence of thrombosis even in the absence of antiphospholipid antibodies6 and there are only limited data describing the risk of thrombosis in patients with an isolated antiphospholipid antibody who do not have SLE. Among 552 randomly selected blood donors, no thrombotic events were observed after 12 months of follow-up among patients found to have aCL.28 Consequently, the risk of thrombosis among healthy patients who are incidentally found to have an antiphospholipid antibody is likely to be low (<1% per year).
The risk of fetal loss and premature birth among asymptomatic women who have antiphospholipid antibodies appears to be increased, based on studies comparing the rates of these outcomes in women considered to be at low risk of pregnancy loss with and without antiphospholipid antibodies.29, 42-44 Comparison of these studies is complicated by differences in the definition of pregnancy loss and the timing of testing for antiphospholipid antibodies. Nevertheless, each of the studies demonstrated a lower live-birth rate in women with antiphospholipid antibodies, ranging from 62% to 84% compared with 90% to 98% in women without these antibodies.
Patients With Fetal Loss but No Prior Thrombosis. The risk of thrombosis among women with antiphospholipid antibodies and fetal loss may be increased, based on the results of a retrospective study comparing aspirin with no prophylaxis in 65 nonpregnant women with antiphospholipid antibodies and a history of pregnancy loss.45 During a mean (SD) duration of 8.1 (3.5) years, 20 (59%) of 34 patients who were not treated experienced venous or arterial thrombosis (7.4 per 100 patient-years) compared with a background risk of thrombosis of approximately 1 per 10 000 per year in unselected premenopausal women.46
Patients With Prior Thrombosis. The risk of recurrent thrombosis among patients with antiphospholipid antibodies is based on limited retrospective studies of untreated patients or studies of patients followed up prospectively after their anticoagulant drugs have been discontinued.47 Three prospective studies suggest that there is an increased risk of recurrence, ranging from 10% to 67% per year.26, 48-49 In a large prospective study,26 412 patients with a first episode of venous thromboembolism who completed 6 months of anticoagulation were tested for aCL and followed up prospectively after anticoagulant drugs were discontinued. After 4 years, 20 (29%) of 68 patients with increased aCL had recurrent thrombosis compared with 47 (14%) of 334 patients without aCL (risk ratio, 2.1; 95% CI, 1.3-3.3).26 Most patients included in these studies did not conform to the consensus definition for APS because antiphospholipid antibody testing was performed only once and testing was often performed after recurrence. In patients who received no antithrombotic treatment, retrospective studies report recurrence rates of 0.19 events50 or 0.29 events per year of follow-up.51 These studies report recurrent thrombosis in 52% to 69% of patients during 5 to 6 years of follow-up, regardless of the type of antithrombotic therapy.50-51 The incidence of thrombosis was highest during the first 6 months following discontinuation of warfarin therapy, with an event rate of 1.30 events per year of follow-up.51 Recurrent thrombosis in APS tends to occur in the same vascular distribution as the original event. Patients with venous thrombosis generally have recurrent venous events and patients with arterial thrombosis have recurrent arterial events.50, 52
Risk of Bleeding. Estimates of bleeding risk are derived from studies evaluating anticoagulant therapy in patients with APS. Major bleeding occurs at a frequency of 2% to 3% per year, which is comparable with the bleeding rates observed in patients without APS but who receive anticoagulant therapy.53-54 Patients with antiphospholipid antibodies directed against prothrombin may rarely present with a bleeding diathesis.55
Antithrombotic Treatment of APS
A proposed treatment algorithm of antithrombotic treatment recommendations and corresponding levels of evidence on which the recommendations are based is shown in the Figure.
|
|
|
|
Figure. Algorithm for Antithrombotic Treatment of Patients With Antiphospholipid Antibodies
INR indicates international normalized ratio. Circled capital letters indicate strength of evidence supporting treatment recommendations.
*Importance of transient antiphospholipid antibodies is uncertain.
|
|
|
Venous Thromboembolism. Venous thromboembolism is the most common initial clinical manifestation among patients with APS, occurring in 32% of patients who meet consensus conference criteria for the diagnosis.56 Initial treatment of venous thromboembolism in patients with APS consists of initial unfractionated or low-molecular-weight heparin for at least 5 days, overlapped with warfarin therapy.57 Compared with placebo or untreated control, moderate-intensity warfarin (adjusted to a target international normalized ratio [INR] of 2.0-3.0) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies.58
For long-term treatment of venous thromboembolism, retrospective case series suggested that high-intensity warfarin (INR, >3.0) was more effective than either aspirin or warfarin administered with a target INR of less than 3.0.50-51 However, 2 randomized trials53-54 have shown that high-intensity warfarin is not better than moderate-intensity warfarin (INR, 2.0-3.0) in preventing recurrent thrombosis. In the first trial,53 among 114 patients with APS who were randomized (74% with previous venous thrombosis) and followed up for a mean duration of 2.7 years, the incidence of recurrent thrombosis was 10.7% among patients who received high-intensity warfarin and 3.4% among those who received moderate-intensity warfarin (HR, 3.1; 95% CI, 0.6-15.0). Major bleeding rates were comparable in the 2 groups, occurring in 5.4% of patients treated with high-intensity warfarin and 6.9% of patients receiving moderate-intensity warfarin (HR, 1.0; 95% CI, 0.2-4.8). Overall bleeding rates were also comparable in the 2 groups, occurring in 25% and 19% of patients, respectively (HR, 1.9; 95% CI, 0.8-4.2).53 In the second trial,54 among 109 patients with APS who were randomized (89% had previous venous thrombosis) and followed up for a median duration of 3.6 years, the incidence of recurrent thrombosis was 11.1% among patients who received high-intensity warfarin and 5.5% among those who received moderate-intensity warfarin (HR, 1.97; 95% CI, 0.49-7.89). Bleeding rates were not significantly different in the 2 groups (27.8% vs 14.6%; HR, 2.18; 95% CI, 0.92-5.15).54
Both of these studies were designed to demonstrate that high-intensity warfarin was better than moderate-intensity warfarin for prevention of recurrent thrombosis. Neither study was powered to demonstrate equivalence of the 2 interventions. When the results of the 2 studies were combined in a meta-analysis using Peto method,59 a significant excess of minor bleeding was evident in patients allocated to high-intensity warfarin (OR, 2.30; 95% CI, 1.16-4.58; P = .02).54 The pooled data did not demonstrate a significant difference in recurrent thrombosis (high- vs moderate-intensity: OR, 2.49; 95% CI, 0.93-6.67), total bleeding (OR, 1.73; 95% CI, 0.93-3.31), or major bleeding (OR, 0.73; 95% CI, 0.23-2.31).
The optimal duration of anticoagulation for prevention of recurrent thrombosis in patients with antiphospholipid antibodies is unknown. The risk of recurrence appears to be highest in the 6-month period immediately following discontinuation of anticoagulant drugs but it is unknown whether the absolute risk of recurrence decreases with increasing duration of anticoagulation. In 1 prospective study,26 105 patients with a single positive test result for aCL who were randomly assigned to stop warfarin after 6 months experienced 23 recurrent events compared with 3 recurrences in 106 patients receiving indefinite anticoagulation (HR, 7.7; 95% CI, 2.4-25.0). All patients who experienced recurrent events in the indefinite treatment group had discontinued warfarin before developing recurrent thrombosis. In a second prospective observational study,48 which measured both LA and aCL after presentation with a first episode of venous thromboembolism, the HR for recurrence at 3 months was 4.0 (95% CI, 1.2-13.0) for patients who were antiphospholipid antibody–positive compared with patients who were antiphospholipid antibody–negative. Although these patients received anticoagulant drugs, the incidence of recurrent thrombosis appears to be increased among those with antiphospholipid antibodies compared with those who do not have antiphospholipid antibodies. Prospective studies of patients with APS receiving antithrombotic therapy (mainly warfarin, but also including patients receiving aspirin or no treatment) report an incidence of recurrent thrombosis of 3% to 24% per year.25, 52-54 Retrospective studies report higher recurrence rates, ranging from 53% to 69%.50-51 Consequently, the general consensus is to treat patients with APS and venous thrombosis with indefinite duration of anticoagulation.57
Decisions regarding duration of anticoagulation may also be influenced by the type of antiphospholipid antibody (LA vs aCL or both) and whether the antibody response is persistent. Because there is a perception that LA compared with aCL is more strongly associated with thrombosis, the presence of LA may prompt extended anticoagulation, although this is based on expert opinion only. It is unknown whether anticoagulation can be discontinued in patients whose LA testing becomes negative or if the only laboratory finding is a persistent low-titer aCL.
In conclusion, patients with antiphospholipid antibodies and a first episode of venous thrombosis should be treated with warfarin administered to achieve an INR of 2.0 to 3.0. The optimal duration of anticoagulation is uncertain but based on prospective data suggesting a high rate of recurrence after warfarin discontinuation; indefinite anticoagulation is recommended.
Arterial Thromboembolism. Arterial events in the APS most commonly involve the cerebral circulation, with stroke being the initial clinical manifestation in 13% and transient ischemic attack in 7% of patients with APS.56 The association between APS and other arterial thrombosis, including myocardial infarction, is less certain.60
Warfarin and aspirin appear to be equivalent for the prevention of thromboembolic complications in patients with a first ischemic stroke and antiphospholipid antibodies. In the Antiphospholipid Antibodies and Stroke Study (APASS),25 a prospective cohort study within the randomized double-blind Warfarin Aspirin Recurrent Stroke Study61 that compared warfarin (INR, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death, patients were classified into 2 groups based on the presence or absence of antiphospholipid antibodies. Among the 1770 patients included in APASS, there was no difference in the risk of thrombotic events in patients treated with warfarin (relative risk [RR], 0.99; 95% CI, 0.75-1.31) compared with aspirin (RR, 0.94; 95% CI, 0.70-1.28) and no difference in the risk of bleeding. The presence of either LA or aCL was not predictive of recurrent thrombotic events, with 24.2% of patients with antiphospholipid antibodies and 24.0% of patients without antiphospholipid antibodies having recurrent events at 2 years (adjusted RR, 0.98; 95% CI, 0.80-1.20).
Based on the APASS data, patients with first ischemic stroke and a single positive antiphospholipid antibody test result who do not have another indication for anticoagulation may be treated with aspirin (325 mg/d) or moderate-intensity warfarin (INR, 1.4-2.8).62 Aspirin is likely to be preferred because of its ease of use and lack of need for laboratory monitoring.
Antithrombotic Treatment of APS in Pregnancy
The optimal treatment of pregnant women with antiphospholipid antibodies and 1 or more fetal losses after 10 weeks' gestation without thrombosis is controversial. A systematic review63 of 13 randomized and quasi-randomized trials involving 849 pregnant women with a history of pregnancy loss and antiphospholipid antibodies found that combination therapy with unfractionated heparin (5000 units subcutaneously twice daily) and aspirin (75-81 mg/d) significantly reduced pregnancy loss compared with aspirin alone (RR, 0.46; 95% CI, 0.29-0.71). However, this particular comparison was examined in only 2 trials involving 140 patients.64-65 The combination of low-molecular-weight heparin (5000 units subcutaneously daily) and aspirin (75 mg/d) compared with aspirin alone did not significantly reduce pregnancy loss (RR, 0.78; 95% CI, 0.39-1.57), based on 1 trial of 98 patients.66 Aspirin (50-81 mg/d) compared with placebo or usual care did not reduce the rate of pregnancy loss in 3 trials (RR, 1.05; 95% CI, 0.66-1.68).67-69 Low doses of subcutaneous unfractionated heparin (5000 units twice daily) appear to be as effective as high-dose heparin (10 000 units twice daily) (RR, 0.83; 95% CI, 0.29-2.38).64
Consensus recommendations suggest that women with antiphospholipid antibodies and a history of 2 or more early pregnancy losses or 1 or more late pregnancy losses who have no prior history of thrombosis receive treatment with combination aspirin and heparin (unfractionated or low-molecular-weight) during pregnancy.8 Aspirin (81 mg/d) should be started with attempted conception and heparin (5000-10 000 units every 12 hours) or low-molecular-weight heparin in prophylactic doses (enoxaparin, 1 mg/kg or 40-80 mg; dalteparin, 5000 units; or nadroparin, 3800 units, all administered once daily) should be started when a viable intrauterine pregnancy is documented and continued until late in the third trimester.70
CONTROVERSIES
Antithrombotic Prophylaxis in APS
The treatment of patients who are incidentally found to have an antiphospholipid antibody and have no prior thrombosis has not been adequately studied, except in patients with SLE. Consensus opinion suggests low-dose aspirin (81 mg/d) may be considered for asymptomatic patients who are not pregnant.71
Optimal Treatment of First Noncerebral Arterial Thrombosis
The optimal treatment of patients who have antiphospholipid antibodies and non–central nervous system arterial thrombosis is uncertain. Many patients with myocardial infarction and antiphospholipid antibodies are treated empirically with long-term warfarin therapy administered to achieve an INR of 2.0 to 3.0.
Optimal Therapy for Recurrent Thrombosis During Warfarin Treatment
Treatment of patients with APS who have recurrent thrombotic events is uncertain.72 For patients not receiving anticoagulant drugs, immediate initiation of anticoagulation with heparin followed up by long-term warfarin is indicated. Patients with recurrent thrombotic events despite warfarin pose a challenge for clinicians. The INR at the time of recurrence is important; an INR below the target therapeutic range represents inadequate anticoagulation as opposed to warfarin failure. These patients may be treated in the same manner as a patient presenting with new thrombosis without warfarin. Possible treatment options for recurrent thrombosis despite warfarin in the target INR range include increasing the intensity of warfarin anticoagulation to achieve a higher target INR (target INR, 2.5-3.5 or 3.0-4.0), switching from warfarin to therapeutic doses of unfractionated heparin or low-molecular-weight heparin, or adding an antiplatelet agent to warfarin. Plasma exchange or intravenous immune globulin, particularly in patients with catastrophic APS, have also been suggested.73
CONCLUSIONS
Since initial reports of an association between aCL and thrombosis and fetal death,74 much of the research has focused on the pathogenesis and clinical features of APS. Prospective studies on the optimal treatment of thrombosis in APS have focused primarily on venous thrombosis and ischemic stroke. The results of these studies indicate that patients with antiphospholipid antibodies and venous thrombosis should be treated with long-term (potentially indefinite) anticoagulation with warfarin administered to achieve an INR of 2.0 to 3.0. Either moderate-intensity warfarin or aspirin is acceptable for patients with antiphospholipid antibodies and a first episode of stroke. Prospective studies addressing the issue of primary antithrombotic prophylaxis in asymptomatic patients with antiphospholipid antibodies are in progress.75-76 These and other well-designed prospective studies are required to complete the understanding of the optimal treatment of patients with antiphospholipid antibodies and APS.
AUTHOR INFORMATION
Corresponding Author: John W. Eikelboom, MBBS, Department of Medicine, McMaster University, Hamilton General Hospital McMaster Clinic, 237 Barton St E, Hamilton, Ontario, Canada L9K 1H8 (eikelbj{at}mcmaster.ca).
Author Contributions: Dr Eikelboom had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Eikelboom.
Acquisition of data: Lim, Eikelboom.
Analysis and interpretation of data: Lim, Crowther, Eikelboom.
Drafting of the manuscript: Lim, Eikelboom.
Critical revision of the manuscript for important intellectual content: Crowther, Eikelboom.
Study supervision: Eikelboom.
Financial Disclosures: None reported.
Funding/Support: No funding was received for this review. Dr Lim is the recipient of the International Society on Thrombosis and Haemostasis/Sanofi-Aventis Clinical Research Fellowship. Dr Crowther is a Career Investigator of the Heart and Stroke Foundation of Canada. Dr Eikelboom holds a Tier II Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes of Health Research.
Author Affiliations: Department of Medicine, McMaster University, Hamilton, Ontario.
REFFERENCES
| |
1. Wassermann A, Neisser A, Bruck C. Eine serodiagnostische Reaction bei Syphilis [German]. Dtsch Med Wochenschr. 1906;32:745-746.
2. Gharavi AE, Sammaritano LR, Wen J, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21:94-99.
WEB OF SCIENCE
| PUBMED
3. Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies: a prevalence study. Biol Psychiatry. 1990;27:863-870.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
4. Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol. 1990;93:771-775.
WEB OF SCIENCE
| PUBMED
5. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-1311.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
6. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991;66:520-524.
WEB OF SCIENCE
| PUBMED
7. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
FREE FULL TEXT
8. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):627S-644S.
FREE FULL TEXT
9. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost. 2003;1:1435-1442.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
10. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
FREE FULL TEXT
11. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717-2723.
FREE FULL TEXT
12. de Groot PG, Horbach DA, Simmelink MJ, van Oort E, Derksen RH. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus. 1998;7(suppl 2):S32-S36.
PUBMED
13. Satoh A, Suzuki K, Takayama E, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. 1999;26:1715-1720.
WEB OF SCIENCE
| PUBMED
14. de Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost. 2005;3:1854-1860.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
15. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European Antiphospholipid Forum. Thromb Haemost. 2001;86:575-583.
WEB OF SCIENCE
| PUBMED
16. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost. 1995;74:1597-1603.
WEB OF SCIENCE
| PUBMED
17. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med. 2002;126:1424-1429.
WEB OF SCIENCE
| PUBMED
18. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
WEB OF SCIENCE
| PUBMED
19. Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment: performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost. 2002;88:583-586.
WEB OF SCIENCE
| PUBMED
20. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus. 2002;11:269-275.
FREE FULL TEXT
21. Harris EN. Special report: the Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990;94:476-484.
WEB OF SCIENCE
| PUBMED
22. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3:1231-1238.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
23. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005;3:1160-1165.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
24. Audrain MA, El-Kouri D, Hamidou MA, et al. Value of autoantibodies to beta(2)-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:550-553.25. The APASS Writing Committee. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-584.
FREE FULL TEXT
26. Schulman S, Svenungsson E, Granqvist S, Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332-338.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
27. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20:231-236.
WEB OF SCIENCE
| PUBMED
28. Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72:209-213.
WEB OF SCIENCE
| PUBMED
29. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161:369-373.
WEB OF SCIENCE
| PUBMED
30. Tsapanos V, Kanellopoulos N, Cardamakis E, et al. Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman. Arch Gynecol Obstet. 2000;263:111-115.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
31. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691.
FREE FULL TEXT
32. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444-451.
WEB OF SCIENCE
| PUBMED
33. Finazzi G. The Italian registry of antiphospholipid antibodies. Haematologica. 1997;82:101-105.
FREE FULL TEXT
34. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15-22.
FREE FULL TEXT
35. Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004;35:736-741.
FREE FULL TEXT
36. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996;87:489-493.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
37. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995;10:3301-3304.
FREE FULL TEXT
38. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:614-620.
WEB OF SCIENCE
| PUBMED
39. Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992;167:26-32.
WEB OF SCIENCE
| PUBMED
40. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337:148-153.
FREE FULL TEXT
41. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25:191-193.
WEB OF SCIENCE
| PUBMED
42. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100:909-913.
WEB OF SCIENCE
| PUBMED
43. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med. 1994;120:470-475.
FREE FULL TEXT
44. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555-559.
WEB OF SCIENCE
| PUBMED
45. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001;44:1466-1467.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
46. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
FREE FULL TEXT
47. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II: optimal anticoagulant therapy for thrombosis. Thromb Res. 2005;115:3-8.
WEB OF SCIENCE
| PUBMED
48. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
FREE FULL TEXT
49. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639.
FREE FULL TEXT
50. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-308.
FREE FULL TEXT
51. Khamashta MA, Cuadrado MJ, Mujic F, Taub MA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-997.
FREE FULL TEXT
52. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-536.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
53. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
FREE FULL TEXT
54. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-853.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
55. Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus. 1999;8:560-564.
FREE FULL TEXT
56. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-1027.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
57. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-428S.
FREE FULL TEXT
58. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706-715.
FREE FULL TEXT
59. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
WEB OF SCIENCE
| PUBMED
60. Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus. 2005;14:691-696.
FREE FULL TEXT
61. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
FREE FULL TEXT
62. Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus. 2003;12:508-513.
FREE FULL TEXT
63. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005(2):CD002859.
PUBMED
64. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584-1589.
WEB OF SCIENCE
| PUBMED
65. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253-257.
FREE FULL TEXT
66. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408-413.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
67. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol. 1997;176:1099-1100.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
68. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? a randomized controlled trial. Am J Obstet Gynecol. 2000;183:1008-1012.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
69. Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997;12:1567-1572.
FREE FULL TEXT
70. Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003;12:524-529.
FREE FULL TEXT
71. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12:499-503.
FREE FULL TEXT
72. Dentali F, Manfredi E, Crowther M, Ageno W. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005;3:2121-2123.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
73. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534.
FREE FULL TEXT
74. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211-1214.
WEB OF SCIENCE
| PUBMED
75. Erkan D, Yazici Y, Harrison MJ, Peterson M, Sammaritano L, Lockshin MD. APLASA study: primary thrombosis prevention in asymptomatic antiphospholipid antibody (APL) patients with low-dose aspirin (ASA) [abstract]. Lupus. 2002;11:573a.
76. Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun. 2000;15:249-253.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
Clinical Review Section Editor: Michael S. Lauer, MD. We encourage authors to submit papers for consideration as a Clinical Review. Please contact Michael S. Lauer, MD, at lauerm{at}ccf.org.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Treatment of Antiphospholipid Antibody Syndrome
Denis Wahl and Veronique Regnault
JAMA. 2006;296(1):42-43.
EXTRACT
| FULL TEXT
Treatment of Antiphospholipid Antibody Syndrome—Reply
Wendy Lim, Mark Crowther, and John Eikelboom
JAMA. 2006;296(1):43.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Neurolupus
Joseph and Scolding
PN 2010;10:4-15.
ABSTRACT
| FULL TEXT
Evaluation and management of stroke
Cucchiara
ASH Education Book 2009;2009:293-301.
ABSTRACT
| FULL TEXT
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-{beta}2-glycoprotein I complexes to phospholipid bilayers
Rand et al.
Blood 2008;112:1687-1695.
ABSTRACT
| FULL TEXT
Venous thromboembolism in women
Rathbun
Vasc Med 2008;13:255-266.
ABSTRACT
Antiphospholipid syndrome dilemmas still to be solved: 2008 status
Shoenfeld et al.
Ann Rheum Dis 2008;67:438-442.
FULL TEXT
Lupus: improving long-term prognosis
Doria and Briani
Lupus 2008;17:166-170.
ABSTRACT
Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature
Erre et al.
Lupus 2008;17:50-55.
ABSTRACT
A 29-Year-Old Man With Pulmonary Complications of a Thrombotic Disorder
Rose and Sajkov
Chest 2007;132:2008-2011.
FULL TEXT
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Garcia et al.
Blood 2007;110:3122-3127.
ABSTRACT
| FULL TEXT
Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Avcin and Silverman
Lupus 2007;16:627-633.
ABSTRACT
Perinatal Implications of the Antiphospholipid Syndrome
Smith and Druzin
NeoReviews 2007;8:e206-e213.
ABSTRACT
| FULL TEXT
Proposed Relationship Between Intravenous Immunoglobulin and Thrombosis in Renal Transplant Recipients
Duronio et al.
The Annals of Pharmacotherapy 2007;41:354-358.
ABSTRACT
| FULL TEXT
The Antiphospholipid Syndrome
Rand
ASH Education Book 2007;2007:136-142.
ABSTRACT
| FULL TEXT
Hemostasis and thrombosis
Crowther and Abshire
ASH-SAP 2007;2007:361-407.
FULL TEXT
Consultative hematology
McCrae et al.
ASH-SAP 2007;2007:466-505.
FULL TEXT
Acute Pulmonary Embolism: Part I: Epidemiology and Diagnosis
Piazza and Goldhaber
Circulation 2006;114:e28-e32.
FULL TEXT
Treatment of antiphospholipid antibody syndrome.
Wahl and Regnault
JAMA 2006;296:42-43.
FULL TEXT
Thrombosis in Infants and Children
Schneppenheim and Greiner
ASH Education Book 2006;2006:86-96.
ABSTRACT
| FULL TEXT
|
